Reviewed by Dr. Elena Vance, DOLast reviewed 4 sources cited
Quick Summary
Mounjaro (tirzepatide) and Victoza (liraglutide) are both incretin-based therapies. In clinical trials, Mounjaro showed greater weight loss (22.5% vs 3.2%).
See the comparison table below for detailed side-by-side data.
Mounjaro vs Victoza: Full Comparison
| Feature | Mounjaro(tirzepatide) | Victoza(liraglutide) |
|---|---|---|
| Active Ingredient | tirzepatide | liraglutide |
| Drug Class | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA Approved | 2022-05-13 | 2010-01-25 |
| Approved Indications |
|
|
| Route | subcutaneous injection | subcutaneous injection |
| Frequency | Once weekly | Once daily |
| Starting Dose | 2.5 mg weekly | 0.6 mg daily |
| Maintenance Dose | 5 mg, 10 mg, or 15 mg weekly | 1.2 mg or 1.8 mg daily |
| Max Dose | 15 mg weekly | 1.8 mg daily |
| Weight Loss (%) | 22.5% | 3.2% |
| A1C Reduction | 2.4% | 1.1% |
| Key Trial | SURMOUNT-1 (72 weeks) | LEADER (188 weeks) |
| List Price | $1,023-$1,176/month | $950-$1,100/month |
| With Insurance | $25-$150/month (varies by plan) | $25-$150/month (varies by plan) |
| Savings Card | $25/month (Lilly savings card, commercially insured) | $25/month (Novo Nordisk savings card, commercially insured) |
Side Effects: Mounjaro vs Victoza
| Side Effect | Mounjaro | Victoza |
|---|---|---|
| Nausea | 12-18% | 28% |
| Diarrhea | 12-17% | 17% |
| Decreased appetite | 5-11% | 9% |
| Vomiting | 5-9% | 11% |
| Constipation | 6-7% | 6% |
| Dyspepsia | 5-8% | 7% |
| Abdominal pain | 5-6% | Not reported |
| Injection site reaction | 3-5% | Not reported |
| Pancreatitis (rare) | <0.5% | <1% |
| Headache | Not reported | 9% |
Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.
Related Comparisons
Frequently Asked Questions
Sources & References
This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.